CD80 Antibody

CD80 Antibody | 8679 | ProSci

Host: Rabbit

Reactivity: Human, Mouse

Homology: Predicted species reactivity based on immunogen sequence: Rabbit: (71%)

Immunogen: CD80 antibody was raised against a peptide corresponding to 17 amino acids near the amino terminus of human CD80.
The immunogen is located within amino acids 60 - 110 of CD80.

Research Area: Cell Cycle, Cancer, Immunology

Tested Application: E, WB, IHC-P, IF

Application: CD80 antibody can be used for Western blot at 1 - 2 μg/mL. Antibody can also be used for Immunohistochemistry at 2 μg/mL. For Immunoflorescence start at 20 μg/mL.
Antibody validated: Western Blot in mouse samples; Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.

Specificiy: N/A

Positive Control 1: Cat. No. 1287 - EL4 Cell Lysate

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: Predicted: 32 kDa
Observed: 50 kDa

Validation: N/A

Isoform: N/A

Purification: CD80 Antibody is affinity chromatography purified via peptide column.

Clonality: Polyclonal

Clone: N/A

Isotype: IgG

Conjugate: Unconjugated

Physical State: Liquid

Buffer: CD80 Antibody is supplied in PBS containing 0.02% sodium azide.

Concentration: 1 mg/mL

Storage Condition: CD80 antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Alternate Name: CD80 Antibody: CD80 molecule, B7, BB1, B7-1, B7.1, LAB7, CD28LG, CD28LG1

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: CD80, also known as B7-1, is a type I membrane protein that is a member of the immunoglobulin superfamily. Like the related protein CD86, this protein is expressed by antigen-presenting cells, and is the ligand for two proteins at the cell surface of T cells, CD28 and the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) . Binding of this protein with CD28 antigen is a costimulatory signal for activation of the T-cell and induces T-cell proliferation and cytokine production. CTLA-4 binding negatively regulates T-cell activation and diminishes the immune response (1) . Blocking the CTLA-4-CD80/CD86 interaction has been shown to enhance T-cell functions in acute lymphoblastomic leukemia (ALL) , suggesting that this pathway may be an attractive target for future cancer immunotherapy (2) .